Stockscreener 앱 받기
67.08
0.11%
0.075
시간 외 거래:
67.08
0.005
+0.01%
전일 마감가:
$67.00
열려 있는:
$67
하루 거래량:
886.78K
Relative Volume:
0.72
시가총액:
$5.55B
수익:
$1.73B
순이익/손실:
$682.64M
주가수익비율:
8.6701
EPS:
7.7364
순현금흐름:
$411.18M
1주 성능:
+5.86%
1개월 성능:
-4.04%
6개월 성능:
+10.90%
1년 성능:
+17.72%
1일 변동 폭
$65.26
$67.59
1주일 범위
$63.80
$68.87
52주 변동 폭
$35.95
$87.50
PTC 테라퓨틱스 Stock (PTCT) Company Profile
명칭
Ptc Therapeutics Inc
전화
(908) 222-7000
주소
500 WARREN CORPORATE CENTER DRIVE, WARREN, NJ
Compare PTCT vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PTCT
Ptc Therapeutics Inc
|
67.08 | 5.55B | 1.73B | 682.64M | 411.18M | 7.7364 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.05 | 114.72B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
737.45 | 78.67B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
684.50 | 42.38B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
311.10 | 41.75B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
282.72 | 31.33B | 5.36B | 287.73M | 924.18M | 2.5229 |
PTC 테라퓨틱스 Stock (PTCT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-28 | 재개 | Barclays | Overweight |
| 2025-12-01 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-10-20 | 개시 | Wells Fargo | Overweight |
| 2025-06-17 | 개시 | Truist | Buy |
| 2025-05-09 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2025-05-07 | 업그레이드 | Citigroup | Sell → Neutral |
| 2025-03-11 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2025-03-07 | 개시 | Scotiabank | Sector Perform |
| 2024-12-13 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2024-12-03 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-10-10 | 재개 | Raymond James | Mkt Perform |
| 2024-09-04 | 개시 | Robert W. Baird | Outperform |
| 2024-08-26 | 재개 | UBS | Buy |
| 2024-05-20 | 업그레이드 | Raymond James | Underperform → Mkt Perform |
| 2023-12-19 | 다운그레이드 | Morgan Stanley | Equal-Weight → Underweight |
| 2023-12-08 | 개시 | Wells Fargo | Overweight |
| 2023-10-30 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2023-10-27 | 다운그레이드 | Citigroup | Neutral → Sell |
| 2023-10-06 | 다운그레이드 | Truist | Buy → Hold |
| 2023-09-18 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2023-09-15 | 다운그레이드 | Raymond James | Outperform → Underperform |
| 2023-03-17 | 개시 | SVB Securities | Market Perform |
| 2022-12-14 | 개시 | Goldman | Sell |
| 2022-09-12 | 개시 | Jefferies | Buy |
| 2022-09-09 | 개시 | Morgan Stanley | Equal-Weight |
| 2022-09-01 | 개시 | Citigroup | Buy |
| 2022-04-04 | 재개 | Cantor Fitzgerald | Overweight |
| 2021-10-18 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2021-04-26 | 재개 | Credit Suisse | Neutral |
| 2021-03-29 | 업그레이드 | RBC Capital Mkts | Underperform → Sector Perform |
| 2021-02-12 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2021-01-05 | 업그레이드 | Citigroup | Neutral → Buy |
| 2020-11-30 | 다운그레이드 | RBC Capital Mkts | Sector Perform → Underperform |
| 2020-10-30 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2020-10-28 | 개시 | UBS | Neutral |
| 2020-10-07 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2020-08-25 | 개시 | Raymond James | Outperform |
| 2020-04-09 | 업그레이드 | Citigroup | Neutral → Buy |
| 2020-02-20 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2020-02-20 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2019-11-12 | 개시 | SunTrust | Buy |
| 2019-05-13 | 업그레이드 | BofA/Merrill | Neutral → Buy |
| 2019-04-11 | 개시 | Bernstein | Outperform |
| 2018-10-03 | 업그레이드 | BofA/Merrill | Underperform → Neutral |
| 2018-10-01 | 개시 | Cantor Fitzgerald | Overweight |
| 2018-07-19 | 개시 | Credit Suisse | Outperform |
| 2018-06-18 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2018-04-04 | 다운그레이드 | Barclays | Equal Weight → Underweight |
| 2018-01-29 | 재개 | RBC Capital Mkts | Sector Perform |
| 2017-11-16 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2017-10-26 | 다운그레이드 | BofA/Merrill | Neutral → Underperform |
| 2017-10-09 | 다운그레이드 | JP Morgan | Neutral → Underweight |
모두보기
PTC 테라퓨틱스 주식(PTCT)의 최신 뉴스
PTC Therapeutics or Eli Lilly: Which Stock Has More Upside? - Trefis
Between PTC Therapeutics and Eli Lilly, Which Stock Looks Set to Break Out? - Trefis
Fundamentals Check: How sensitive is PTC Therapeutics Inc to inflationPortfolio Return Report & Accurate Intraday Trading Signals - baoquankhu1.vn
PTCT SEC FilingsPtc Therapeutics 10-K, 10-Q, 8-K Forms - Stock Titan
Cinctive Capital Management LP Takes Position in PTC Therapeutics, Inc. $PTCT - MarketBeat
Boxer Capital Management LLC Invests $12.27 Million in PTC Therapeutics, Inc. $PTCT - MarketBeat
What PTC Therapeutics (PTCT)'s FDA Leadership Shift Means For Its Gene and RNA Pipeline Narrative - simplywall.st
Matthew Klein Sells 2,662 Shares of PTC Therapeutics (NASDAQ:PTCT) Stock - MarketBeat
PTC Therapeutics (PTCT) CEO logs RSU vesting and automatic tax share sale - Stock Titan
18 new PTC Therapeutics hires receive stock options, RSUs - Stock Titan
FDA Shift Reframes PTC Therapeutics Regulatory Risks And Reward Profile - Sahm
Insider Sell: Stephanie Okey Sells 15,167 Shares of PTC Therapeu - GuruFocus
Stephanie Okey Sells 15,167 Shares of PTC Therapeutics (NASDAQ:PTCT) Stock - MarketBeat
PTC Therapeutics Director Sells Over $1 Million in Company Stock - TradingView
PTC Therapeutics (PTCT) director exercises options, sells 15,167 shares - Stock Titan
PTCT (NASDAQ: PTCT) insider reports proposed 2,662-share sale - Stock Titan
B. Metzler seel. Sohn & Co. AG Invests $944,000 in PTC Therapeutics, Inc. $PTCT - MarketBeat
FDA ‘blacklist’ in DMD? Legislator slams PTC turndown - bioworld.com
PTC Therapeutics at Barclays Conference: Sephience’s Global Potential By Investing.com - Investing.com Canada
PTCT: Sepiapterin’s rapid PKU launch drives strong growth, with global expansion and pipeline progress - TradingView
PTCT Earnings History & Surprises | EPS & Revenue Results | PTC THERAPEUTICS INC (NASDAQ:PTCT) - ChartMill
PTC Therapeutics Stock Soars 8.88%, Hits Intraday High of $69.17 - Markets Mojo
PTC Therapeutics at Leerink Conference: Strategic Growth in PKU Market By Investing.com - Investing.com Canada
Proposed sale: 15,167 PTCT shares listed by Fidelity (PTCT) - Stock Titan
PTC Therapeutics (+8.9%): FDA Leadership Change Spurs Sector-Wide Rally - Trefis
(PTCT) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Stephanie Okey Sells 6,333 Shares of PTC Therapeutics (NASDAQ:PTCT) Stock - MarketBeat
Neil Gregory Almstead Sells 3,989 Shares of PTC Therapeutics (NASDAQ:PTCT) Stock - MarketBeat
PTC Therapeutics (NASDAQ: PTCT) director sells 6,333 shares at $63.38 - Stock Titan
Executive stock sale by PTC Therapeutics (PTCT) Chief Medical Officer - Stock Titan
PTC Therapeutics (PTCT) CTO spouse sells shares under 10b5-1 trading plan - Stock Titan
PTC Therapeutics (NASDAQ:PTCT) Shares Up 6.9%Time to Buy? - MarketBeat
Jefferies Financial Group Acquires Stake in PTC Therapeutics - National Today
Jefferies Financial Group Inc. Acquires Shares of 1,584,678 PTC Therapeutics, Inc. $PTCT - MarketBeat
PTC Therapeutics EVP & Chief Medical Officer Sells 10,000 Shares - TradingView
Ideas Watch: Will PTC Therapeutics Inc. benefit from government policy2026 Setups & Safe Entry Trade Signal Reports - baoquankhu1.vn
Dividend Watch: Is PTC Therapeutics Inc a stock for growth or value investorsMarket Volume Summary & Weekly Stock Performance Updates - baoquankhu1.vn
Royce & Associates LP Has $2.01 Million Holdings in PTC Therapeutics, Inc. $PTCT - MarketBeat
Fidelity plans resale of PTCT common shares (NASDAQ: PTCT) - Stock Titan
Neil G. Almstead sells multiple PTCT lots (PTCT) — Form 144 details - Stock Titan
PTC Therapeutics, Inc. (PTCT) - DirectorsTalk Interviews
Investment Manager Bets Big on PTCT Stock, Adds 41,000 Shares, According to Recent SEC Filing - Yahoo Finance
Oversold Conditions For PTC Therapeutics (PTCT) - Nasdaq
PTC Therapeutics (PTCT) Gains Edge as Competitor Faces Setback - GuruFocus
PTC Therapeutics Grants Stock Options and RSUs to New Employees - Intellectia AI
Assessing PTC Therapeutics (PTCT) Valuation After Contrasting Quarterly Loss And Full Year Profit Turnaround - Sahm
JPMorgan Chase & Co. Reduces Holdings in PTC Therapeutics, Inc. $PTCT - MarketBeat
PTC Therapeutics vs Merck: Which Is the Stronger Buy Today? - Trefis
GSA Capital Partners LLP Decreases Position in PTC Therapeutics, Inc. $PTCT - MarketBeat
PTC Therapeutics, Inc. (NASDAQ:PTCT) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
16,062 Shares in PTC Therapeutics, Inc. $PTCT Purchased by Private Capital Advisors Inc. - MarketBeat
PTC 테라퓨틱스 (PTCT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.20%
0.06%
자본화:
|
볼륨(24시간):